Overseas Expansion through Global Partnerships
First written in FY2024. 2 of 5 entries say "Reframed", first in FY2025. Latest entry: 2026-03-27.
No other company in this theme has enough history to compare yet.
- 2026-03-27ReframedManagement Planning
「For global expansion, we will select the optimal strategy while considering both partnership and Company-led scenarios.」
Following the termination of the partnership, the Company organized its overseas expansion policy around multiple scenarios, including Company-led development rather than limiting itself to partnerships. - FY2025ReframedAnnual report
「The Company had been partnered with global pharmaceutical company Novo Nordisk A/S for 4 years since 2021. However, as stated in the Company's release dated 29 September 2025, the business partnership was terminated at the other party's initiative.」
The exclusive partnership with Novo Nordisk was terminated in September 2025, and worldwide rights to HS-001 and HS-005 were returned to the Company. The Company moved to considering the direction of its overseas expansion, including securing a new partner or pursuing development independently. - 2026-03-06DroppedGeneral Meetings of ShareholdersSuggests it is closing out
「Novo Nordisk A/S, formerly our business partner, notified us on 29 September 2025 that it would terminate the exclusive technology collaboration and license agreement, citing its focus on its core business areas and a review of its strategy for other areas.」
The exclusive technology collaboration and license agreement with Novo Nordisk was terminated, indicating the end of the overseas expansion thread based on the former partnership. - FY2026-H1AdvancedAnnual report
「As a result of achieving a development milestone under the exclusive technology partnership and license agreement with Novo Nordisk A/S, based on the recent business progress during the interim accounting period, milestone income has been recognized as revenue.」
A development milestone under the exclusive technology partnership and license agreement with Novo Nordisk was achieved, reflecting concrete progress under the partnership. - FY2024First statedAnnual report
「Under the partnership scheme, we grant Novo Nordisk A/S the rights to clinical development, manufacturing and sales worldwide outside Japan, while retaining the marketing rights in Japan, where the two companies will co-commercialize the products and share profits from the Japanese business on a 50:50 basis.」
The Company used a partnership granting Novo Nordisk overseas rights while retaining Japanese rights for joint commercialization and 50:50 profit sharing as a foundation for business expansion.